FDA Updates Opioid Labeling Requirements to Reflect Long-Term Risks

AUGUST 27, 2025

‘Right-Sizing’ Surveillance Intervals for CRC: Considerations for Now and the Future

AUGUST 25, 2025

Access to Oncology Drugs Stymied by Prior Authorization, but Specialty Pharmacists Can Help

AUGUST 22, 2025

Email This Article

POSTED: DECEMBER 12, 2016

SABCS 2016: Buparlisib Improves PFS in BELLE-3 Study, But Toxicity Is Concerning

San Antonio—The combination of PI3K inhibitor buparlisib and endocrine therapy with fulvestrant improved progression-free survival (PFS) in postmenopausal women with hormone receptor–positive/HER2-negative advanced breast cancer compared with fulvestrant alone
A link to this article will be included in this email.

Recipient's Email Address:

Enter email addresses separated by commas if sending to more than one person. (200 characters max)

Your Name:

Your Email Address:

Send me a copy

Personal Message: (Optional)

These email addresses will only be used to send out this message.

Please wait..

Breast Cancer

DECEMBER 12, 2016

SABCS 2016: Buparlisib Improves PFS in BELLE-3 Study, But Toxicity Is Concerning

To read the full story, Log in or Sign up for a Free Account

Check out our new Clinical tab!

We've added an exciting new feature to our website. Click on "Clinical" in the navbar to explore!

The following result is from the NPI Registry Public Search database. You can click on the NPI number to view detailed information and verify its accuracy. If your NPI is not found in this search, you can try searching again using the form below. If you have difficulty finding your NPI number please contact us at web@mcmahonmed.com

First Name

Last Name

Organization/Institution

State

NPI	Name	Organization/ Institution	State	Zip Code	Taxonomy	Credential	Select